Disclosure
HCommentary
AI commentary · Not investment advice
What happened
Hanall Biopharma disclosed its preliminary consolidated results for the third quarter of 2026 (July 1 to September 30) in a fair disclosure filed on October 28, 2026. Revenue was KRW 39.9 billion, operating profit was KRW 1.3 billion, and net income was KRW 3.1 billion.
In the company's terms
Compared with other periods, revenue fell 9.9% from KRW 44.3 billion in the previous quarter and 2.2% from KRW 40.8 billion a year earlier. Operating profit fell 77.2% from KRW 5.6 billion in the previous quarter and rose 265.1% from KRW 0.3 billion a year earlier. Net income turned to profit from a loss of KRW 19.2 billion in the previous quarter, and rose 924.2% from KRW 0.3 billion a year earlier.
What changes for shareholders
These figures are preliminary and may differ from the final confirmed results.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist